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Abstract: Acute myelogenous leukemia (AML) is an aggressive hematological malignancy.
The pathophysiology of the disease depends on cytogenetic abnormalities, gene mutations, aberrant
gene expressions, and altered epigenetic regulation. Although new pharmacological agents have
emerged during the last years, the prognosis is still dismal and new therapeutic strategies are
needed. The transcription factor nuclear factor-κB (NF-κB) is regarded a possible therapeutic target.
In this study, we investigated the alterations in the global gene expression profile (GEP) in primary
AML cells derived from 16 consecutive patients after exposure to the NF-κB inhibitor BMS-345541.
We identified a profound and highly discriminative transcriptomic profile associated with NF-κB
inhibition. Bioinformatical analyses identified cytokine/interleukin signaling, metabolic regulation,
and nucleic acid binding/transcription among the major biological functions influenced by NF-κB
inhibition. Furthermore, several key genes involved in leukemogenesis, among them RUNX1 and
CEBPA, in addition to NFKB1 itself, were influenced by NF-κB inhibition. Finally, we identified a
significant impact of NF-κB inhibition on the expression of genes included in a leukemic stem cell
(LSC) signature, indicating possible targeting of LSCs. We conclude that NF-κB inhibition significantly
altered the expression of genes central to the leukemic process.
Keywords: acute myelogenous leukemia; nuclear factor-κB; transcriptomic; cytokines; metabolism;
immune system; intracellular signaling
1. Introduction
Acute myelogenous leukemia (AML) is a heterogeneous and aggressive malignancy characterized
by bone marrow accumulation of immature leukemic blasts that suppress normal hematopoiesis [1].
The median age at the time of diagnosis is 65–70 years [1], and for younger patients receiving the
most intensive therapy, the median long-term AML-free survival is 45–50% [2]. However, older and
unfit patients with severe comorbidities cannot receive the most intensive treatment, i.e., highly
cytotoxic chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT), due to an
unacceptable risk of treatment-related mortality [3]. The average survival for those patients receiving
supportive therapy alone is only 2–4 months, and very few survive longer than one year [3]. All these
observations clearly illustrate the need for new and more effective therapeutic approaches with
acceptable toxicity, especially for elderly patients.
Abnormal constitutive activation of intracellular signal transduction could enhance the survival
and proliferation of AML cells and could occur due to genetic abnormalities [4,5]. Several signaling
cascades finally lead to the activation of the transcription factor nuclear factor-κB (NF-κB) [6]. The NF-κB
family of transcription factors was identified more than 30 years ago as a binding interactor for
the κ light chain enhancer in B-lymphocytes [7]. This complex is activated by several stimuli,
including pro-inflammatory cytokines, mitogens, growth factors, and stress-inducing agents [8–10].
NF-κB is involved in the regulation of multiple fundamental cellular processes, including cell
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proliferation, cell survival, intercellular communication, stress responses, regulation of angiogenesis as
well as inflammation, and even carcinogenesis/leukemogenesis [8–10].
Constitutive NF-κB activation has been reported both in patient studies as well as in vitro and
experimental in vivo models of AML [6], and NF-κB seems to of particular importance for the subset
of CD34+ AML cells [11]. These CD34+ leukemic cells are believed to be the main compartment for
leukemic stem cells (LSCs) for most patients, a leukemic cell subset regarded to be important for
chemoresistance and, ultimately, AML relapse [12–14]. Furthermore, several studies suggest a crucial
role of NF-κB in leukemogenesis also through indirect effects mediated by bi-directional crosstalk
between the leukemic cells and their neighboring stromal cells [15,16].
Given the central role of NF-κB in cancer biology, this has also increased the interest for
pharmacological targeting of this transcription factor in cancer therapy [9]. Several NF-κB inhibitors
have been identified [17]. Some of them have entered preclinical and clinical trials [9], including
the pharmacological agent BMS-345541, which selectively interacts with inhibitors of κB (IκB) kinase
(IKK). The inhibition of IKK leads to the decreased phosphorylation of serine residues of IκB with the
subsequent ubiquitination and proteolysis of IκB, and thereby, inhibition of NF-κB-mediated gene
transcription. BMS-345541 is regarded as a highly selective inhibitor of NF-κB function, and previous
studies have shown a high degree of NF-κB inhibition by BMS-345541 [18–20].
The aim of the present study was to investigate the gene expression profile (GEP) associated
with the pharmacological intervention by BMS-345541 in primary human AML cells. Furthermore,
we wanted to identify the major biological systems and signaling pathways that were altered by this
NF-κB inhibitor in primary human AML cells.
2. Materials and Methods
2.1. AML Patient Population and Preparation of Primary AML Cells
The study was approved by the local Ethics Committee (REK III 2013/634, University of Bergen,
Norway) and samples were collected after written informed consent. Our study included 16 consecutive
and thereby unselected patients (11 males and five females; median age 70 years with range 39–87 years),
with high relative and absolute peripheral blood blast counts (>5 × 109/L) (Table 1). All patients
were diagnosed according to the World Health Organization (WHO) criteria [21], and most of
them had de novo disease (Table 1). All AML cell samples were obtained from peripheral blood,
the leukemic cells were isolated by density gradient separation (Lymphoprep, Axis-Shield, Oslo,
Norway), and gradient-separated cells contained at least 95% leukemic blasts. Cells were stored frozen
in liquid nitrogen until used in the experiments [22].
2.2. In Vitro Culture of Human AML Cells Before Analysis of Gene Expression
AML blasts (2 × 106 cells in 2 mL) were cultured in 24 well culture plates (Costar 3524; Cambridge,
MA, USA) for 48 h in StemSpan SFEM™medium (referred to as StemSpan; Stem Cell Technologies;
Vancouver, BC, Canada), supplemented with 100µg/mL of gentamicin. The NF-κB inhibitor BMS-345541
was purchased from Sigma-Aldrich Corp. (St. Louis, MO, US). Stock solutions of BMS-345541 were
prepared in dimethylsulphoxide (DMSO), and the final DMSO concentration in our inhibitor-free
control cultures was the same as in the BMS-345541 containing cultures. The final concentration
used for BMS-345541 was 10 µM; this concentration has also been used in previous studies of in vitro
cultured primary AML cells and has been shown to inhibit the constitutive cytokine release [16,23,24].
The final DMSO concentration did not have any effect on the in vitro proliferation or viability of
cryopreserved primary human AML cells [16,23].
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Table 1. Patient overview. Biological and demographical characteristics of the 16 patients included in the study.
Number Gender Age Etiology FAB CD 34 Hb (g/dL) Platelets (×109/L) Cytogenetics FLT3 NPM1
1 F 87 De novo M0 Pos 8.6 22 Del 5 wt wt
2 M 65 De novo M5 Neg 9.2 213 Normal ITD INS
3 M 39 De novo M3 Pos 7.0 12 t(15;17) wt wt
4 M 78 MDS nt nt 8.3 30 Trisomy 11 nt nt
5 M 63 De novo M5 Neg 7.8 31 Normal wt ins
6 M 82 De novo nt Pos 11.8 50 Trisomy 8 wt wt
7 F 77 MDS M2 nt 10.7 35 Normal ITD INS
8 M 78 De novo M1 Pos 8.3 206 Complex nt nt
9 M 84 De novo M1 Pos 9.0 116 Complex wt wt
10 F 46 De novo M1 Pos 10.8 1182 Inv(16) wt wt
11 M 46 De novo M1 nt 15.4 113 Normal wt INS
12 F 82 Relapse M2 Neg 9.2 16 Normal ITD INS
13 M 42 De novo M5 Neg 10.6 179 Normal ITD INS
14 F 59 De novo M4 Neg nt nt Normal ITD INS
15 M 78 De novo M1 Pos 9.5 35 Normal wt wt
16 M 75 CMML nt nt 10.8 44 Del 12p, Del 7 nt nt
Abbreviations: CMML, chronic myelomonocytic leukemia; Del, deletion; F, female; FAB, French-American-British; Hb, hemoglobin; INS, insertion; ITD internal tandem duplication;
Inv, inversion; M, male: MDS, myelodysplastic syndrome; Neg, negative; nt, not tested Pos, positive; wt, wild type.
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2.3. RNA Preparation, Labelling and Microarray Hybridisation
All microarray experiments were performed using the Illumina iScan Reader, which is based on
fluorescence detection of biotin-labeled cRNA [25]. Total RNA (300 ng from each sample) was reversely
transcribed, amplified, and Biotin-16-UTP-labeled using the Illumina TotalPrep RNA Amplification
Kit (Applied Biosystems/Ambion, USA). The amount and quality of the B biotin-labelled cRNA were
controlled both by the NanoDrop spectrophotometer and by the Agilent 2100 Bioanalyzer before 750 ng
of the biotin-labeled cRNA was hybridized to the HumanHT-12 V4 Expression BeadChip according to
manufacturer’s instructions. The HumanHT-12 V4 BeadChip targets 47,231 probes derived mainly
from genes in the NCBI RefSeq database (Release 38).
2.4. Statistical and Bioinformatical Analyses
The data from the scanning of arrays on the IlluminaScan Reader were investigated in
GenomeStudio (Illumina) and J-Express 2012 (MolMine AS, Bergen, Norway) for quality control
measures [26]. All arrays within each experiment were quintile normalized to be comparable before
being compiled into an expression profile data matrix. The Geneontology (http://geneontology.org/)
database was used to identify ontology annotations. In the analysis of the functional network, we used
the STRING (version 11.0) [27], and the PANTHER databases (version 14.0) to search for gene ontology
profiles [28]
3. Results
3.1. NF-κB Inhibition Alters the Global GEP of Primary Human AML Cells
We first investigated the alterations in the global GEP for primary AML cells derived from the
16 patients; the cells were cultured with and without the NF-κB inhibitor BMS-345541. The global
profiles for BMS-345541-exposed cells were compared with the GEP for cells from the corresponding
inhibitor-free control cultures for each of the 16 patients. We performed a feature subset selection
(FSS) analysis, and based on this analysis, we were able to discriminate between genes upregulated
and downregulated in the BMS-345541-containing cultures. A total of 277 genes showed a fold
change greater than ±3 and a t-score of at least ±2.5, and these 277 genes were regarded to be highly
discriminative between cells cultured with either BMS-345541 or medium alone (Table S1). Among the
277 genes, 183 genes were downregulated, and 94 were upregulated.
We performed a principal component analysis (PCA) based on the 277 highly discriminative
genes; the first principal component was highly discriminative for cells in the intervention cultures
compared to cells in control cultures (Figure 1A). This observation was further supported by the highly
discriminative hierarchical clustering with distance matrix analysis (Figure 1B), indicating a high
degree of correlation between cells in intervention cultures versus control cultures. A hierarchical
cluster analysis was finally performed (Pearson’s correlation, complete linkage; Figure 1C. This last
analysis showed that the upregulated and downregulated genes in the two distinct clusters were highly
consistent through the two groups, and the obtained profile could be used to highly discriminate the
intervention and control cell cultures.
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Figure 1. Effects of nuclear factor-κB (NF-κB) inhibition on the global gene expression profile of
primary human acute myelogenous leukemia (AML) cells: We performed a feature subset selection
(FSS) analysis and identified 277 genes that were differently expressed (i.e., fold change at least ±3,
t-score at least ±2.5) when comparing cultures treated with the NF-κB inhibitor BMS-345541 and the
corresponding control cultures. Most of these genes (183/277) were downregulated, and only 94 were
upregulated in cells exposed to the NF-κB inhibitor. (A) By performing a principal component analysis
(PCA), we identified the first principal component to be highly discriminative for cells exposed to the
NF-κB inhibitor compared with control cells. (B) Discriminative hierarchical clustering with the distance
matrix. The correlation visualization matrix displays the pairwise correlation between the 32 different
cell cultures. Green and blue colors indicate high positive or negative correlation, respectively, between
samples. (C) A hierarchical cluster analysis based on the 277 differentially expressed genes was finally
performed (Pearson’s correlation, complete linkage). Green color indicates upregulated genes, and blue
color indicates downregulated genes in the BMS-345541 cultures compared with controls. The red
bar to the right in the figure indicates intervention cultures, whereas purple indicates control cultures.
The hierarchical cluster analysis clearly identified two patient/cell clusters that corresponded to the
BMS-345541 containing and control cultures and two gene expression clusters that corresponded to up-
and downregulated genes.
Cells 2020, 9, 1677 6 of 19
3.2. Overrepresentation Analysis Shows That Genes Involved in Metabolism and Immune Regulation Are
Downregulated by NF-κB Inhibition
We further investigated the class of genes and their annotations to identify specific pathways
affected by the downregulated genes. We then performed an overrepresentation analysis based on all
183 highly discriminative genes that were downregulated by NF-κB inhibition. Using the Geneontology
database supported by the Panther database, we were able to perform a gene ontology (GO) enrichment
analysis. By using the term Biological process, we investigated the overrepresentation of GO-terms
among the 183 genes (Table S1), and by exploring the Reactome pathways, we identified several
GO-terms enriched among the genes downregulated by NF-κB inhibition (Figure 2). We analyzed
both terms for overrepresentation of genes, i.e., the number of genes among the downregulated
genes compared with the number of genes expected to be found by coincidence, and in addition,
we investigated the fold enrichment score. Some of the highly enriched GO-terms reflect biologic
processes known to be involved in leukemogenesis and include immune system/signaling, protein
metabolism, interleukin signaling, translation and interferon signaling together with NF-κB activation
itself (Figure 2).
3.3. Genes Encoding Proteins That Are Crucial for Fundamental Cellular Functions Are Influenced by
NF-κB Inhibition
We analyzed the major GO terms associated with the genes that were downregulated by NF-κB
inhibition. We used the PANTHER database to classify proteins encoded by the 183 downregulated
genes [28]. We then searched for functional classification analysis and used the three major terms
(i) Pathway, (ii) Protein class, and (iii) Cellular process (Figure 3). In each of these classes, we further
investigated the three largest subcategories/terms. In the setting of pathway analysis, we identified
inflammation mediated by the chemokine/cytokine signaling pathway, the apoptosis signaling pathway,
and cholesterol biosynthesis to be the three major pathways (Figure 3 left). By investigating the single
proteins of these three pathways, we identified several proteins encoded by downregulated genes
involved in leukemogenesis, including NFKB1, CXCL10, and IL1B [5,6,29]. In the setting of protein
class analysis, we identified nucleic acid binding, enzyme modulators, and transcription factors to
be the three largest terms (Figure 3 middle). By investigating single encoding genes of these protein
classes, we identified several proteins known to be involved in leukemogenesis, including NFKB1,
RUNX1, and CEBPA [6,30,31]. Finally, for the term cellular process, we identified cellular metabolic
process, cellular component organization, and cellular response to stimulus as the three major terms
(Figure 3 right). By investigating single proteins included in these terms, we identified several proteins
previously linked to leukemogenesis, including SOD2, BID, and RALA [32,33].
3.4. Network Analysis Identified Several Protein Networks to be Central in NF-κB Inhibition
To further investigate whether the identified differences in GEP could be translated to a molecular
network profile, we searched for interactions between the proteins encoded by the significantly
downregulated genes in BMS-345541 exposed AML cells. We then used the STRING database [27].
Based on these downregulated genes, we identified a network based on a protein–protein interaction
(PPI) enrichment p-value < 0.0005, i.e., the identified proteins show significantly more interactions
than would be expected by coincidence alone. The results from this network analysis based on the
downregulated genes are presented in Figure 4, and we identified four main interaction subsets.
The main characteristics of the encoded proteins for each of the four networks are summarized in
Table S2:
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Figure 2. Gene ontology GO enrichment analysis of genes being downregulated by nuclear factor-κB
(NF-κB) inhibition: We performed a GO enrichment analysis based on the 183 genes that were
downregulated by NF-κB inhibition; the terms Biological Process and Reactome Pathways were used
for annotation. The GO-terms identified by a false discovery rate (FDR) <0.05 are presented in the figure.
(A) For each of the identified GO-terms, we present the number of identified genes (blue column) and
the number of genes that would be expected to be identified by coincidence (orange column). (B) The
fold enrichment score, i.e., representing the degree to which the identified downregulated genes are
over-represented in the terms, is also presented for the identified GO-terms.
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Figure 3. Classification of downregulated genes by BMS-345541 inhibition: We classified the 183 genes downregulated by nuclear factor-κB (NF-κB) inhibition
according to their biological function by using the PANTHER database. As indicated at the top of the figure, we selected the three major terms pathway (left), protein
class (middle), and cellular process (right) for detailed analyses. We were then able to identify major subgroups within each of these three main terms (upper part of
the figure), as indicated by the corresponding diagrams in the lower part of the figure. For each of the three main terms (i.e., pathway/protein class/cellular process),
we then selected the three largest subgroups of downregulated genes (see the lower part). For each main term, the three selected subgroups/terms are presented as
partly overlapping circles, and the individual genes included in the various subgroups are indicated.
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Figure 4. Network analysis of genes with downregulated expression after NF-κB inhibition: The figure
presents a network analysis based on the proteins encoded by the 183 genes that were downregulated
by NF-κB inhibition. By using the STRING database, we were able to identify a strong network where
each individual node represents a single, protein-coding gene, and the number of connections indicates
the number of specific and functionally relevant molecular interactions (i.e., functional interactions
but not necessarily a direct binding between the molecules). Four extensive networks were identified
by this analysis, as indicated in the Figure. 1, an nuclear factor-κB 1 (NFKB1) network; 2, a network
including several mitochondrial ribosomal protein large (MRPL) proteins; 3, a network including
several small nuclear ribonucleoprotein polypeptides (SNRP) molecules; and 4, a network including
many interferon-induced protein with tetratricopeptide repeats (IFIT)
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Leukemogenesis-chemosensitivity. This network included 10 proteins, and previous studies have
shown that all the encoded proteins are involved in leukemogenesis and chemosensitivity in human
AML (Table S2). This network included NFKB1 that is the DNA binding subunit of the NF-κB protein
complex, and thereby, is essential for the transcriptional regulation by NF-κB [34].
Mitochondrial proteins. The second network of genes encoding several mitochondrial ribosomal
protein large (MRPL) was also identified by this analysis of downregulated genes. Seven of the eight
genes encoded proteins involved in mitochondrial protein synthesis/ribosomes, and mitochondrial
markers, including different MRPLs, which have recently been linked to carcinogenesis [35,36]. The last
gene encoded a mitochondrial protein involved in energy metabolism.
Spliceosomal proteins/RNA. The third network mainly including small nuclear ribonucleoprotein
polypeptides (SNRP) was identified. Their biological functions are not fully understood, although they
are believed to be important for the spliceosome [37].
Interferon (IFN)-induced proteins. The interferon-induced protein with tetratricopeptide repeats
(IFITs) constitutes an important network that probably interacts with the transcription factors RUNX1,
CEBPB, and CEBPA. IFITs are prominent interferon-stimulated genes, with critical molecular, biological,
and oncogenic functions, and they are possibly important in the development and maintenance of
malignant diseases [38].
To conclude, our interaction analysis of genes downregulated by NF-κB inhibition identified
four main interaction networks, and previous studies suggest that all four downregulated networks
included several genes encoding proteins that were important for leukemogenesis and chemosensitivity
in human AML.
3.5. Genes Upregulated by NF-κB Inhibition Constitute a Less Pronounced Profile Compared to
Downregulated Genes
Only 94 of the 277 differentially expressed genes were upregulated after exposure to the NF-κB
inhibitor. Furthermore, the upregulated genes showed relatively few interactions, and no annotations
were significant by the GO enrichment analysis. However, by using the STRING database, we were able
to identify three minor networks of upregulated genes (Figure S1). The functional characteristics of the
encoded proteins by these three networks are briefly described in Table S3, including the two proteins
IGFBP7 and NR4A2 that have recently been linked to AML leukemogenesis [39,40].
3.6. The Leukemic Stem Cell GEP Signature Was Significantly Altered by NF-κB Inhibition
NF-κB has previously been linked to LSCs in AML models [11], and we, therefore, investigated
the alterations in a previously identified LSC GEP [14]. These authors identified a 17 gene LSC score
based on identified LSC cell fractions, and this score could also be used for prognostication of AML
patients [14]. We identified these 17 genes in our microarray data set. AKR1C3 was the only of these
17 genes that was included among the 277 genes that were downregulated after NF-κB inhibition
(Table S1). However, we found that the expression profile based only on these 17 genes was consistently
altered by NF-κB inhibition, 10 of these genes were then downregulated, and seven genes were
upregulated. By performing a hierarchical clustering based on these 17 genes, we found the profile
to be highly discriminative between patient cells from control cultures and patient cells exposed to
the BMS-345541 inhibitor; there was only one outlier in each group (Figure 5A). These observations
were further supported by a principal component analysis based on the LSC gene expression profile,
indicating that principal components 1 and 2 were able to identify 32.1% and 15.8% of the variance,
respectively (Figure 5B). Furthermore, a hierarchical clustering analysis with distance matrix also
illustrated how the 17 gene LSC profiles could discriminate between cells cultured with and without
BMS-345541 (Figure 5C). Finally, by performing an ANOVA based on the 17 identified LSC genes,
we could identify the t-score and fold change for each individual LSC profile gene, and these results
are present in Figure 5D.




Figure 5. Alteration in acute myelogenous leukemia (AML) leukemia stem cell (LSC) gene 
expression profile (GEP) AML LSC GEP by nuclear factor-κB (NF-κB) inhibition: An LSC gene Figure 5. Alteration in acute myelogenous leukemia (AML) leukemia stem cell (LSC) gene expression
profile (GEP) AML LSC GEP by nuclear factor-κB (NF-κB) inhibition: An LSC gene expression
profile, including 17 genes has been identified in a previous study [14], and we, therefore, compared
these 17 gene profiles in primary AML cells incubated with and without the BMS-345541 inhibitor.
(A) Hierarchical clustering analysis was performed (Pearson’s correlation, complete linkage) based
on the 17 genes. The green color indicates upregulated genes in the BMS-345541 containing cultures
compared with the corresponding control cultures, whereas the blue color indicates downregulation.
Red bars at the top of the figure indicate BMS-345541-containing cultures, and the purple bars indicate
control cultures. The hierarchical cluster analysis identified two patient cell clusters corresponding to
cells with/without BMS-345541, except for two outliers. (B) Principal component analysis based on the
same 17 genes included in the LSC gene profile showed that the first and second principal components
could explain 32.1% and 15.8% of the variance, respectively. (C) Discriminative hierarchical clustering
with the distance matrix analysis indicated a high degree of correlation between cells from control
cultures and the corresponding BMS-345541-containing cultures. (D) ANOVA analysis based on the
17 identified LSC-associated genes identified the t-score and fold change for each of these 17 genes,
and these observations are present in the diagram.
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4. Discussion
Aberrant NF-κB signaling associated with gene transcription modulation is involved in the
initiation, maintenance, and progression of several malignant diseases and are also common in
hematological malignancies, including AML [9]. Hence, pharmacological inhibition of NF-κB is
regarded as a possible therapeutic approach both as monotherapy and in combination with conventional
chemotherapeutic agents. However, a better understanding of how such pharmacological targeting
affects primary AML cells is needed. In our present study, we investigated primary AML cells derived
from 16 consecutive AML patients. Our selection of patients reflects the expected heterogeneity of AML
with regard to etiology, i.e., secondary or de novo, and biology of the disease, including cytogenetic
and molecular genetic abnormalities [2]. Based on the culture of the primary AML cells under highly
standardized in vitro conditions, we were able to compare GEP obtained from inhibitor-free control
cultures with cells cultured in the presence of the NF-κB inhibitor BMS-345541. GEP in AML is a
well-established methodological strategy with clinical relevance, it reflects cytogenetic and molecular
genetic subclassifications, and has a prognostic impact [41,42]. Altered GEP during interventions
could be an important tool for understanding the effect on biological systems. In the present study,
we discovered a significant alteration in the transcriptomic profile after NF-κB intervention; 277 genes
with significantly altered expression were identified, and these genes were highly discriminative for the
intervention versus the control cells. Given the central role of NF-κB in the regulation of transcription,
it is not surprising that the alteration in the transcriptomic profile is significant. These observations are
also consistent with findings in other malignancies showing that NF-κB inhibition could significantly
alter the transcriptomic profile [43].
AML is a very heterogeneous disease [1,4], this heterogeneity includes transcriptional
regulation [41,44]. Leukemic cells derived from different patients, may therefore differ regarding the
effect of NF-κB inhibition. We investigated only 16 patients, and this is too few patients to characterize
differences between AML patients regarding the effect of NF-κB inhibition based on GEP of their
leukemic cells. Despite the patient heterogeneity, we detected significant effects of NF-κB inhibition
on AML cell gene expression profiles. The effects described in the present study should, therefore,
be regarded as effects of NF-κB inhibition that are common for all or most AML patients across their
heterogeneous biological characteristics. We would emphasize that additional studies are needed for a
more detailed characterization of pharmacological effects of NF-κB inhibition that may be important
for subsets of patients or single patients.
We used the HumanHT-12 V4 Expression BeadChip technology for analysis of global gene
expression profiles. Methodological approaches based on sequencing technology are now available and
represent an alternative methodological strategy. However, in our opinion, the chip methodology used
in our present study article also represents a highly standardized and reproducible methodological
approach and for these reasons represent an acceptable methodological strategy.
We investigated the NF-κB inhibitor BMS-345541. This is a well-characterized inhibitor, and the
mechanisms behind its inhibitory effect have been characterized in previous molecular studies, including
Western blot studies of several cancer cell lines [17,18,45]. By using this well-characterized inhibitor,
the risk of off-target effects is reduced. Furthermore, this inhibitor, as well as the proteasome inhibitor
bortezomib, another drug with NF-κB inhibitory activity, could reduce the constitutive cytokine release
by primary human AML cells [24,46,47]. These previous observations at the protein level are also
consistent with present results describing an effect of NF-κB inhibition on cytokine-induced signaling.
We used network analysis to further evaluate the possible biological relevance of our present
observations, and we then identified four interacting clusters (see Figure 4 and Table S2). First,
one of the networks included 10 genes, and previous studies have shown that all 10 encoded proteins
are relevant for leukemogenesis and chemosensitivity in human AML, and may thus be possible
therapeutic targets in human AML (see Table S2 for details and references). Second, another subset of
genes encoded proteins that are important for mitochondrial functions, and thereby, probably also for
the regulation of cellular metabolism. The targeting of mitochondria or cellular metabolism is now
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regarded as a possible therapeutic strategy in human AML [48–51]. Third, several downregulated
genes encoded interacting proteins that are important for the spliceosome or RNA binding/transport.
Genes encoding splicing factors could be mutated in human AML and these mutations seem to have
an adverse prognostic impact [52,53]. RNA splicing/metabolism may, therefore, represent a possible
therapeutic target in AML. Finally, a last network included genes that encode IFN-induced proteins;
these proteins may also be important in AML [38]. Taken together, our present studies suggest that
NF-κB inhibition inhibits several intracellular molecular mechanisms that now are regarded as possible
therapeutic targets in future AML therapy. NF-κB inhibition may, therefore, represent inhibition of
several therapeutic targets in human AML cells through the use of single therapeutic agents. However,
protein expression is regulated and depends on several mechanisms and not only the regulation at the
mRNA level, and for these reasons, our network analyses have to be interpreted with care.
We aimed to classify the genes that showed altered expression after NF-κB inhibition, we then used
well-recognized bioinformatical tools. Based on our 183 downregulated genes after NF-κB inhibition,
we applied an enrichment analysis in search for the overrepresented GO-terms. We identified several
terms, including terms representing functional classes of genes know to encode proteins that are
important in leukemogenesis. Based on the analysis, three major biological systems seemed to be
among the most influenced by NF-κB inhibition, including (i) cytokine and interleukin (IL) signaling,
(ii) metabolic regulation, and (iii) immune system/cell communication. In the first class, i.e., cytokine and
interleukin signaling, especially IL-4, IL-10, IL-13, and IFN seemed to be important. These observations
are in accordance with previous studies describing a role for NF-κB in the regulation of constitutive
cytokine release by primary human AML cells [16,54–56].
Several cytokines could be constitutively released by AML blasts [16] and are important for
intercellular communication in the bone marrow microenvironment [29]. Metabolic targeting is now
considered as a therapeutic strategy in human malignancies, including AML [57]. This is especially true
for the 10–15% of AML patients with mutations in the metabolic genes isocitrate dehydrogenase (IDH)
1 or 2, resulting in increased levels of oncometabolites [58]. However, altered metabolic regulation
seems to be important also in other AML subclasses [59]. Based on these considerations, it is interesting
that metabolic regulators are targeted by NF-κB inhibition. This was most prominent when using the
PANTHER GO-terms where the metabolic process was the term with the most differentially expressed
genes. This is further supported by the fact that both mitochondrial function, adipocytes, and the
central metabolic pathway Peroxisome proliferator-activated receptor α (PPARA) appear to be affected
by NF-κB inhibition in AML based on the GO-mapping. Finally, the effect of NF-κB inhibition on
genes involved in immunoregulation is also in accordance with previous AML studies [6], and with
the initial discovery of NF-κB as an enhancer of B-cell functions [7]. These features are again related
to the alterations in cytokine-associated genes, as chemokines and interleukins are important for the
functions of immunocompetent cells. Finally, the importance of NF-κB in the transcriptional regulation
of several genes involved in leukemogenesis is also reflected in our study of several single genes that
were altered by NF-κB inhibition, e.g., NFKB1, CXCL10, and IL1B [5,6,29].
We identified nucleic acid binding, enzyme modulators, and transcription factors to be the three
largest terms in our protein class analysis, and previous studies have shown that several of the
downregulated genes are involved in leukemogenesis. First, several genes that are frequently mutated
in AML were downregulated, including RUNX1 and CEBPA, which are mutated in 10–15% and 5–10%
of patients, respectively. Noteworthy, RUNX1 mutations are associated with adverse prognosis [2]
and are often detected in secondary AML [30]. In contrast, CEBPA mutations, at least in the case of
double-strand mutations, are usually associated with chemosensitivity and favorable outcome [2,31].
(ii) Second, the expression of several genes encoding inflammatory cytokines (e.g., IL-1β, CXCL5,
CXCL10, CCL2) were also significantly downregulated by NF-κB inhibition. These observations suggest
that the effects of NF-κB inhibition on single cytokines should be regarded as a network effect [5,29],
and our results confirmed that NF-κB is an important regulator of the cytokine network [16,29,60].
Finally, genes encoding central regulatory proteins involved in leukemogenesis were downregulated
Cells 2020, 9, 1677 14 of 19
by NF-κB inhibition, including BID, encoding a proapoptotic member of the Bcl-2 protein family, and
thereby, possibly being antagonistic to the Bcl-2 inhibitor venetoclax [61]. The Ras-related protein
Ral-A (RALA) was also downregulated; this protein functions as a molecular switch to activate several
fundamental biological processes of many different cancer cells [62]. Noteworthy is also the altered
expression of NFKB1 that encodes the Rel specific transcription inhibitor that is a part of the DNA
binding subunit of the NF-κB complex [9,34]. Compensatory upregulation of this gene in response
to NF-κB inhibition is probably consistent with this. Our network analysis also identified a network
associated with NF-κB inhibition as well as altered expression of MRRPL, SNRP, and IFIT genes that
possibly are involved in malignant cell transformation [35–38]. Of particular interest in the setting of
AML is SNRP that is crucial for the spliceosome [37]; this effect may be relevant, especially for patients
with mutations in spliceosome genes [4].
NF-κB inhibition could alter a 17-gene expression profile associated with LSCs. The elimination
of LSCs by antileukemic therapy is probably of particular importance, since these cells are believed to
be at the top of the hierarchy and be responsible for AML relapse [13]. They are also characterized by
an LSC-specific gene expression signature [14]. Herein, we demonstrated that NF-κB inhibition could
alter this transcriptomic signature, indicating a possible role for NF-κB inhibition in the targeting of
the leukemic stem cells.
In the present study, we used the NF-κB inhibitor BMS-345541 that selectively interacts with
the inhibitor of κB (IκB) kinase (IKK), and it is regarded as a highly selective inhibitor of NF-κB [6].
However, several agents could inhibit NF-κB function through various direct and indirect mechanisms.
It should, therefore, be emphasized that the alterations in GEP described in this study might not be
specific for NF-κB inhibition in AML cells, but should possibly be regarded as a model for the potential
biological effects of NF-κB inhibition in cancer patients. In Table 2, we have summarized some in vitro
studies of NF-κB inhibition in AML. Several of these studies describe antiproliferative, proapoptotic,
antiangiogenic, or antimigratory effects of NF-κB inhibition. Furthermore, given the considerable
heterogeneity between AML patients, additional effects may be detected for single patients or subsets
of patients. Our study, including 16 patients, is too small to detect differences in NF-κB inhibition
between patients, i.e., subsets defined by cytogenetic or molecular genetic alterations. Our study rather
describes the effects that are common for all or most AML patients.
Table 2. Summary of important in vitro studies of NF-κB inhibition in AML.
Drug Patients/AML Cell Lines Major Findings References
AS602868 61 patients Induced cytotoxicity and alteration in GEP, especially effectson immune-related genes. [63]
Xanthumol U937 and HL-60 cell lines Suppression of antiapoptotic gene expression, increasedapoptosis in leukemia cells. [64]
Reseveratrol OCIM2 and OCI-AML3 celllines, five patient samples
Proapoptotic and antiproliferative effects in suspension
cultures and colony-formation assays, decreased constitutive
cytokine release
[65]
Curcumin SHI1 cell lines Inhibition of proliferation and cell migration, alteredtranscriptional regulation, decreased cytokine secretion. [66]
Celastrol HL-60 cell line Antiproliferative and proapoptotic effects [67]
BAY 11-7082 OCI-AML3 cell line Antiproliferative and antiangiogenic effects [68]
5. Conclusions
NF-κB is an important transcription factor involved in AML leukemogenesis, and it is also
regarded as a potential therapeutic target. However, the biological effects of NF-κB inhibition are
only partly known, and to the best of our knowledge, this is the first study to describe the effects of
NF-κB inhibition on the global gene expression profiles of primary AML cells derived from a group of
consecutive and thereby unselected patients. We identified a significant and highly discriminative gene
expression profile associated with NF-κB inhibition. We identified cytokine and interleukin signaling,
alterations in metabolic systems, altered cellular communication, and transcriptional regulation among
the altered cellular functions after NF-κB inhibition. Additional animal studies are needed before
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NF-κB inhibition can move into clinical studies, and BMS-345541 may not be the best inhibitor to be
tried in the first clinical studies, but animal investigations have identified new agents that have NF-κB
inhibitory effects and could be used as oral treatment [69,70].
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/7/1677/s1.
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